^

Health

Tagere forte

, medical expert
Last reviewed: 23.04.2024
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

The drug Tager forte refers to one of the most effective medicines to combat anaerobic and protozoal infections. Therefore, this medication copes well with infectious diseases caused by the above pathogens.

In the medical classification, the drug Tager forte refers to a pharmacotherapeutic group of drugs with antimicrobial properties that are intended for systemic use. This highly effective agent belongs to a subgroup of antibacterial drugs that are produced on the basis of imidiazole (or are derivatives of 5-nitroimidiazole).

A high degree of antimicrobial activity of the drug is noted in the fight against a large number of obligate anaerobic bacteria and protozoa. Therefore, the drug is characterized by a wide range of effects. Its merits include the ability to neutralize the vital activity of some representatives of facultative anaerobic microflora (microaerophiles), which positively affects the healing of those diseases that these microorganisms are excited.

Indications Tagere forte

Indications for the use of the drug Tager forte are as follows:

  • Therapy of intestinal and extraintestinal amebic dysentery.
  • Treatment of trichomoniasis and lambliasis.
  • Treatment of bacterial vaginosis, as well as vaginosis caused by Trichomonas.
  • Therapy of urethritis, provoked by Trichomonas.

Release form

The form of release of the drug Tager forte is as follows:

  • The drug is produced in white oval tablets, like capsules, coated with a shell, on one side of which there is a dividing strip.
  • Each tablet contains one gram of active ingredient - secnidazole.
  • Of the auxiliary components, each tablet includes microcrystalline cellulose, corn starch, gelatin, sodium starch glycolate, colloidal silica, magnesium stearate.
  • The shell of each tablet is coated with hydroxypropylmethylcellulose, macrogol 6000, titanium dioxide (E171).
  • The drug is released in a cardboard box, in which there is a contouring cell plate with two tablets of the drug contained in it. In addition, the package contains instructions for using the drug.

Pharmacodynamics

Pharmacodynamics of the drug Tager forte is as follows:

  • Active active substance of the drug - seknidazol - is a half synthetic derivative of nitroimidazole.
  • Secnidazole has antibacterial and antiprotozoal effect.
  • The mechanism of action of the drug is as follows: the active component of the drug is able to penetrate into the cell of the microorganism causing the infectious disease. Then, secnidazole is incorporated into the metabolic processes inside the foreign cell by the reduction of the 5-nitro group under the action of reductases. After that, the restored secretidasol begins to interact with the DNA of microbes and bacteria, thereby producing disturbances in its spiral structure, breaking the chains and suppressing the production of nucleic acids therein. Thus, secnidazole leads to the death of bacterial cells and cells of the simplest.
  • The medicament Tager forte is effective against the following microorganisms: Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia.

trusted-source[1], [2]

Pharmacokinetics

The pharmacokinetics of the Tager forte preparation is as follows:

  • The active substance of the drug, seksidazole, can be absorbed eighty percent after oral administration.
  • The maximum amount of the active ingredient in the blood serum is observed after three to four hours after the drug is consumed.
  • The concentration of the drug in the blood plasma is linear when receiving therapeutic doses from half to two grams.
  • The half-life of the active substance from the blood plasma is about twenty to twenty-five hours.
  • Seknidazol differs ability to penetrate the placental barrier during pregnancy and is observed in breast milk when breastfeeding.
  • A larger amount of absorbed drug is slowly excreted from the body through urine. This occurs as follows: within seventy-two hours, sixteen percent of the drug dose is allocated.

Dosing and administration

The following way of using the drug and the corresponding dose are recommended:

  • The drug is taken orally for half an hour before meals. The tablet is washed down with enough water.
  • Doses for adult patients:
    • with intestinal amebic dysentery - two grams in a single dose;
    • with amebic processes in the liver - one and a half grams once a day for five days;
    • with trichomoniasis and bacterial vaginosis for the patient and his partner - two grams in a single dose;
    • with giardiasis - two grams, as a one-time daily dose for three days.
  • Doses for patients of childhood (from the age of twelve):
    • with amoebic dysentery and giardiasis - when calculating thirty mg of the drug per kg of body weight, that is, from one to one and a half grams in a single dose;
  • The above dose can be divided into two doses for three days (with similar diseases as mentioned above).
  • It is forbidden to drink alcohol of any strength during the treatment process, and also not less than one day after the end of therapy.

trusted-source[3], [4], [5], [6]

Use Tagere forte during pregnancy

Use of the drug Tager forte during pregnancy and lactation period is prohibited.

If it is necessary to use the drug, breast-feeding should be interrupted or completely discontinued.

Contraindications

Hypersensitivity to one or more of the components of the drug. To a greater extent, this applies to imidazole derivatives.

Available in the anamnesis pathological states of the formula of blood.

Presence of organic diseases of the central nervous system.

The drug is contraindicated for use during pregnancy and lactation in women.

The drug is not prescribed in childhood until the age of twelve, because the safety and efficacy of seknidazole is not known for children of this age group.

The drug is not allowed to be used by people who are forced to drive a car or any other complex machinery.

Side effects Tagere forte

In the treatment with Tager forte, the following side effects were identified:

  • The active component of the drug - seksidazol - is well tolerated by patients. Therefore, a large number of side effects occur in a light form and for a short amount of time.
  • When taking Tiger forte preparation, symptoms of a disturbance of the functioning of the gastrointestinal tract may appear, namely signs of dyspeptic phenomena, nausea, vomiting, gastralgia, metallic taste in the mouth, glossitis (inflammation of the tongue), stomatitis.
  • Perhaps the emergence of allergic reactions (reddening of the skin, rashes, itching and so on).
  • Manifestations of dizziness, headaches and other neurological disorders are observed in rare cases.
  • Rare side effects are the presence of tremors and seizures.
  • When receiving a small number of patients, symptoms of a nervous system disorder can be observed: signs of ataxia, peripheral neuropathy, movement coordination disorders, paresthesia.
  • Among the side effects of the drug in rare cases, there are signs of reversible moderate leukopenia, as signs of a disorder in the functioning of the hematopoiesis system.
  • Signs of side effects of the drug Tager forte, usually expressed in a moderate form and do not affect the treatment of the patient.
  • In case of obvious effects of side effects of the drug, it is necessary to stop taking Tager forte.

trusted-source

Overdose

Information on cases of accidental or deliberate drug overdose is absent due to the fact that these cases were not observed.

Overdose with Tager forte stimulates an increase in signs of a side effect of the drug.

When an overdose of medicament occurs symptoms of leukopenia and ataxia.

The method of treatment of a patient with an overdose of the drug:

  • cancellation of the use of the medicinal product;
  • gastric lavage;
  • appointment of maintenance and symptomatic therapy.

trusted-source[7]

Interactions with other drugs

As a result of the practice of using the drug Tager forte, the following interactions of the drug with other medicines have been identified:

  • The active substance of the drug - secnidazole - is able to stimulate anticoagulant (anti-folding) effect of coumarin derivatives. This increases the risk of bleeding due to certain health problems in the patient.
  • It is forbidden to combine the reception of seksidazol with disulfiramine because in this case the combination of these substances is observed the appearance of delirious seizures, as well as dizziness.

trusted-source[8], [9], [10]

Storage conditions

The storage conditions for Tager forte are as follows:

  • The drug should be kept in a dry place and protected from light.
  • The drug should be kept at a temperature of no more than twenty-five degrees Celsius.
  • The drug should be carefully hidden from the reach of children.

trusted-source[11], [12]

Shelf life

The shelf life of the drug Tager forte is thirty-six months.

It is forbidden to use the medicinal product for treatment after the expiration date indicated on the package.

trusted-source[13]

Attention!

To simplify the perception of information, this instruction for use of the drug "Tagere forte" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.